Allogene Therapeutics (NASDAQ: ALLO) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its rivals? We will compare Allogene Therapeutics to related businesses based on the strength of its risk, valuation, profitability, earnings, analyst recommendations, dividends and institutional ownership.
This is a breakdown of current ratings for Allogene Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Allogene Therapeutics Competitors||834||2774||6059||261||2.58|
This table compares Allogene Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Allogene Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
Insider and Institutional Ownership
51.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 15.7% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Allogene Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Allogene Therapeutics Competitors||$897.63 million||$190.37 million||-1.33|
Allogene Therapeutics’ rivals have higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Allogene Therapeutics beats its rivals on 7 of the 11 factors compared.
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.